50
Participants
Start Date
June 21, 2022
Primary Completion Date
June 30, 2028
Study Completion Date
June 30, 2029
Loncastuximab tesirine 150 µg/Kg
Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.
Loncastuximab tesirine 75µg/Kg
Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
RECRUITING
Emory University, Atlanta
RECRUITING
University of Miami, Miami
RECRUITING
Vanderbilt University, Nashville
RECRUITING
City of Hope National Medical Center, Duarte
Collaborators (1)
ADC Therapeutics S.A.
INDUSTRY
University of Miami
OTHER